



CHINA-MSD HIV/AIDS PARTNERSHIP

Our company's Foundation committed \$36 million over twelve years (2005–2016) to address the growing burden of HIV/AIDS in China and to help support the National HIV/AIDS Prevention and Control Action Plan.

The China-MSD HIV/AIDS Partnership (C-MAP) was officially launched in 2007 in Sichuan Province as an innovative public-private partnership to establish a comprehensive and effective HIV/AIDS prevention and control model. C-MAP was the first large-scale partnership between the Chinese government and a multinational company to focus on HIV/AIDS prevention and control.

Since 2007, C-MAP has successfully helped build an overall HIV prevention and treatment network in Sichuan Province. The partnership also piloted an integrated disease management model in ethnic minority regions. It has achieved significant progress in raising HIV awareness among the general public, improving HIV testing rates, improving the capacity of local healthcare providers, and expanding access to and quality of antiretroviral treatment (ART).

In its second phase (2014–2016), C-MAP worked to strengthen integrated HIV treatment capacity and coverage and to promote cooperation between the township and county health systems of Sichuan Province's Liangshan Prefecture. The program also expanded to new sites in Chongqing Municipality and Fujian Province. The partnership continued its focus on improving HIV/AIDS management and treatment services by strengthening the capacity of healthcare workers to support effective patient referrals and by promoting quality HIV care through health worker training in effective HIV diagnosis, treatment and disease management.

C-MAP focused on the following key program objectives:

1. Promoting HIV counseling and testing to improve early diagnosis of HIV-positive (HIV+) patients and timely entry into care and treatment
2. Improving effective referral of newly diagnosed HIV+ patients to ART services
3. Enhancing the capacity and capability of primary healthcare workers to support effective patient referral and promote high-quality HIV treatment services
4. Expanding ART coverage for eligible HIV+ patients
5. Increasing patients' adherence to antiretroviral treatment

C-MAP operations concluded in 2016.

PERFORMANCE

The second phase of C-MAP, launched in 2014, achieved significant progress in treatment coverage, patient referrals and adherence, and physician training. The performance indicators below reflect aggregate data from across the Sichuan Province, Liangshan Prefecture; Chongqing Municipality; and Fujian Province.

C-MAP PHASE II METRICS	2014	2015	2016
Investment by our company's Foundation (in millions)	\$3.00	\$2.50	\$0.50
HIV TESTING, AND PATIENT REFERRALS AND TREATMENT			
Number of people who have received HIV testing and counseling	236,625	125,405	NR
HIV test and detection efficiency ratio (percentage of new HIV+ detection among number of HIV tests)	0.07%	0.11%	NR
Percentage and number of successful patient referrals to treatment services ¹	90.20%	95.30%	NR
	(5,595/6,200)	(5,867/6,158)	NR
ANTIRETROVIRAL TREATMENT (ART)			
Newly diagnosed adult AIDS patients who are receiving ART	3,764	4,528	NR
Adult AIDS patients who are receiving ART (cumulatively)	9,200	14,842	NR
Newly diagnosed children with HIV who are receiving ART	31	40	NR
Children with HIV who are receiving ART (cumulatively)	81	129	NR
Proportion of eligible patients receiving ART	80.90%	79%	NR
Proportion of patients who are adherent to ART for 12 months	94.10%	95.30%	NR
Rate of viral load suppression (viral load less than 400 copies) among patients who are adherent to ART for 12 months	74.60%	73.40%	NR
HEALTH CARE CAPACITY-BUILDING			
Physicians who received training	1,856	1,928	NR

¹ Successful referral is defined as those patients who are referred from a testing site to an ART center and remain on treatment for at least one month.

NOTE: C-MAP program operations largely concluded at the beginning of 2016.